Last updated on February 2019

Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT)


Brief description of study

The primary objective of the study is to determine whether pemafibrate administered twice daily will delay the time to first occurrence of any component of the clinical composite endpoint of:

  • nonfatal Myocardial Infarction (MI)
  • nonfatal ischemic stroke
  • hospitalization for unstable angina requiring unplanned coronary revascularization; or
  • Cardio Vascular (CV) death.

Detailed Study Description

A multi-regional clinical trial with participating sites planned in the following countries pending approval from the applicable oversight authorities:

  • Argentina
  • Brazil
  • Bulgaria
  • Canada
  • Colombia
  • Czech Republic
  • Denmark
  • France
  • Germany
  • Hungary
  • India
  • Israel
  • Japan
  • Mexico
  • Netherlands
  • Poland
  • Romania
  • Russian Federation
  • Slovakia
  • South Africa
  • Spain
  • Ukraine
  • United Kingdom
  • United States

Clinical Study Identifier: NCT03071692

Contact Investigators or Research Sites near you

Start Over

Takekawa Naika Clinic

Higashiosaka-shi, Japan
2.56miles
  Connect »

Iwasaki Naika Clinic

Higashiosaka-shi, Japan
2.57miles
  Connect »

Shiraiwa Medical Clinic

Kashiwara-shi, Japan
2.58miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.